Acadia Pharmaceuticals reported phase 2/3 trial results for remlifanserin in Alzheimer’s disease psychosis, where the high dose failed to reach statistical significance but indicated positive efficacy trends. Although the drug showed a clean safety profile, the low effect size on the primary endpoint raises concerns about its clinical usefulness and the likelihood of replicating results in phase 3. The analyst lowered the probability of phase 3 success to 25%, citing efficacy and trial design issues. Despite this, Acadia’s valuation remains supported by other products Nuplazid and Daybue, with the pipeline offering potential long-term growth regardless of remlifanserin’s outcome.
Following the recent trial results for remlifanserin, Acadia Pharmaceuticals' stock on Pluang shows a notable decline. As of Sep 24, 2026 23:03 WIB, ACAD trades at USD 23.44, down 7.83% for the day, with a market cap of $4.38 billion. The stock remains between its 52-week low of $20.06 and high of $30.57, reflecting ongoing investor caution amid the drug's uncertain prospects.
